Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of Automated Best Practice Advisories on Provider Response to CYP2C19 Genotyping Results for Patients on Clopidogrel.

Journal of pharmacy practice - 1 Jun 2023

Petry Natasha J, Curtis Breanna, Feldhege Erica, Khan Shahjahan, Leedahl David D, Breidenbach Jesse L, Hines Lindsay

Abstract excerpt

ObjectiveThe study objective was to examine provider acceptance and genotyping responses to a best practice advisory (BPA) concerning clopidogrel and CYP2C19 intermediate and poor metabolizers within the context of a new pharmacogenomics program at a Midwestern health system. Other secondary objectives analyzed included appropriate BPA firing, the distribution of alleles in study population, indications for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clopidogrel
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Pharmacogenetics

Share to Platelet Aggregation Inhibitors

Source

Identifiers

PMID: 34622701
DOI: 10.1177/08971900211049589

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of Automated Best Practice Advisories on Provider Response to CYP2C19 Genotyping Results for Patients on Clopidogrel.PMID 34622701Read ↗

Implementation of clopidogrel pharmacogenetic clinical decision support for a preemptive return of results program.Semantic proximity Read ↗

Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection.Semantic proximity Read ↗

A surveillance tool to support quality assurance and research in personalized medicine.Semantic proximity Read ↗

Physician response to implementation of genotype-tailored antiplatelet therapy.Semantic proximity Read ↗

Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy.Semantic proximity Read ↗

Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.Semantic proximity Read ↗

Real-World Implementation of CYP2C19 Pharmacogenetic Testing in Clopidogrel-Treated Patients: Insights from French Clinical DataSemantic proximity Read ↗

Interventional cardiologists' attitudes towards pharmacogenetic testing and impact on antiplatelet prescribing decisions.Semantic proximity Read ↗

Perspective on CYP2C19 genotyping test among patients with acute coronary syndrome - a qualitative study.Semantic proximity Read ↗

A Clinician-Driven Automated System for Integration of Pharmacogenetic Interpretations Into an Electronic Medical RecordSemantic proximity Read ↗

Clinical pharmacogenetics implementation: approaches, successes, and challenges.Semantic proximity Read ↗

Prescriber Adoption of SLCO1B1 Genotype-Guided Simvastatin Clinical Decision Support in a Clinical Pharmacogenetics Program.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.